Arena Pharmaceuticals Initiates Second And Third Pivotal Trials Evaluating Lorcaserin For The Treatment Of Obesity
Dec 15th 2007Drug InformationClinical Trials
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced the initiation of patient screening in the second and third Phase 3 pivotal trials evaluating the efficacy and safety of its lead drug candidate, lorcaserin hydrochloride, for weight management in overweight and obese patients. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
